The US Food and Drug Administration (FDA) has approved CRISPR based gene therapy for the first time in history. This approval is an important milestone in the field of genetic medicine, as CRISPR technology has revolutionized the field of gene editing. With the help of this technique, scientists can now directly change DNA and treat diseases that were previously considered impossible or difficult.
On December eight, 2023, the U.S. Food and Drug Administration (FDA) accredited Casgevy, a groundbreaking CRISPR-based gene editing therapy from Vertex Pharmaceuticals and CRISPR Therapeutics, for sickle cellular disease (SCD).
The approval changed into never critically unsure, because the remedy—additionally called exagamglogene autotemcel, or exa-cel—established marvelous medical effects dating returned to the first affected person, Victoria Gray, who was dosed in July 2019. The FDA also introduced approval of some other SCD gene remedy, Bluebird Bio’s lentiviral remedy, Lyfgenia. However, that approval comes with a black field warning given the incidence of uncommon instances of blood cancers in patients.
What is CRISPR and How Does It Work?
CRISPR (Clustered regularly interspaced short palindromic reepeats) is a state -of -the -art gene editing technique, capable of cutting and modifying any part of the genome accurately. It is also known as 'Jean's scissors.
The biggest feature of CRISPR technology is that it can remove unwanted or defective genes and put the right gene, which eliminates the cause of the disease. With the help of this technique, treatment is possible at every level of development from conceiving point to development.
First Approved CRISPR Therapy Specialty
The first CRISPR therapy sanctioned by the FDA, which has been developed by a company called "CRISPR Therapeutics", is designed to treat a rare genetic disease. The name of this disease is "sickle cell anemia", which is associated with the deformity of red blood cells in the body and causes patients to face serious health problems. Through this therapy, healthy blood cells are produced by modifying the affected cells, which improves the life quality of the patient.
New Hope in Treating Genetic Diseases
With this historical decision of gene therapy, a new revolution has started in the treatment of genetic diseases. This can help in treating not only sickle cell anemia but also other serious diseases such as Thalassemia, cancer and some inherited diseases. Experts say that CRISPR technology will bring a permanent solution for these diseases in future, which will improve the lives of millions of patients.
Experts’ Opinion and Future Possibilities
Scientists and physicians consider this decision a major success in medical science. He has said that this approval is an indication that CRISPR technology is proving safe and effective in human medicine. However, there are also some moral and safety aspects of this technique, which continue to research and monitor. In the future Crispr will be used to treat more diseases, which will open new dimensions in the medical field.
Elation and Safety Issues
There are also some moral questions related to the use of CRISPR technology. Because this technique makes permanent changes in the gene, scientists have to ensure that its side effects are minimal and it remains safe for humanity.
The FDA has imposed stringent criteria while approving the safety of the patients. In addition, experts believe that rules should be made globally for the correct and responsible use of this technique.
Historical Achievement for Genetic Medicine
Getting approval for CRISPR gene therapy for the first time by FDA is a historical achievement for genetic medicine. This technique is not only going to change the direction of medicine but has also brought a new ray of hope in the lives of millions of patients.
In the coming years, the use of CRISPR will be possible to solve many other unseen and complex diseases. This is an important step to improve the quality of human life and revolutionize the medical world.
Rewriting the Clinical System
But in spite of these and different clinical milestones, the enjoy of SCD patients has no longer superior to the same degree. As the past due technology journalist Sharon Begley placed it: The U.S. Healthcare device is killing adults with sickle cellular disease.
And at the same time as FDA approval of Casgevy is a second for birthday celebration, this method gained’t help the sizeable majority of patients international. As Dhruv Khullar wrote in the New Yorker: If we virtually need to cure sickle cell disease, modifying genomes will only get us to date. We’ll need to rewrite our medical system, too.
Even today, more than a century after the primary case document, SCD patients are still subject to profiling and suspicion through medical institution staff as they are trying to find ache medications.
There may be no population of sufferers whose healthcare and outcomes are more suffering from racism” than those with SCD, hematologists Alexandra Power-Hays, MD, and Patrick McGann, MD, wrote inside the New England Journal of Medicine. Making matters worse, many SCD patients lack basic statistics and/or get admission to to general capsules and screening tools that might ward off disorder headaches.
As the gene and mobile remedy field celebrates every other approval for precision remedy, we have to be ashamed that fewer than one in five kids with SCD are prescribed antibiotics or the established anticancer drug hydroxyurea, which reinforces ranges of HbF.
To have teenage patients who in no way heard the word hydroxyurea—that’s preposterous, McGann pronounces. There isn’t even a countrywide registry of SCD patients, so no one can say exactly how many people are affected.
More than 50 years in the past, President Nixon signed the Sickle Cell Control Act, growing new treatment centers and multiplied funding. But the benefit become brief lived. In a study published in 2020, Duke University hematologist John J.
Strouse, MD, and co-workers argued that by way of many metrics, which include federal investment, philanthropic guide, and new drug approvals, help for SCD lags that afforded cystic fibrosis, even though cystic fibrosis impacts kind of one third of the number of sufferers within the United States as SCD.
